

Prof. Dr. Volker Schirmacher

Department: Cellular Immunology

CV:

VOLKER SCHIRRMACHER

Prof. Dr. rer. nat.

Personal

Date of birth: 1943

Place of birth: Wentdorf (near Hamburg), Germany

Academic Education and Appointments

1962 – 1967

Studies of Biochemistry at the Universities of Hamburg, Berlin and Tübingen

Qualification: Diplom in Biochemistry

1967 – 1970

PhD Thesis in Immunology at the Institute of Genetics of the University of Köln supervised by *Prof Or. K. Rajewsky*

1971 – 1973

Postdoc with a DFG-stipend at Karolinska-Institute in Stockholm, Sweden with *Prof Or. H. Wigzell*

1973 – 1976

Senior-Research-Fellow at the Transplantation Immunology Unit in London

(The London Hospital Medical College) with *Prof Or. H. Festenstein*

1976 – 2008

Head of "Division of Cellular Immunology" at the DKFZ

(German Cancer Research Center) Heidelberg

1979

Habilitation in Immunology at the Faculty of Pharmacy, University of Heidelberg

1986

Appointment to Ordinarius and C4-Professor

Chairman for Immunology at Heidelberg University

1987 – 1989

Elected President of the "Sektion Experimentelle Krebsforschung" of the Deutsche Krebsgesellschaft

1990 – 1992

Elected President of the International "*Metastasis Research Society*"

2001

Elected Representative for Germany as EACR Council Member

Since 2009

Scientific Director of Tumor-Immunology at IOZK

(Immunological and Oncological Center Cologne) Köln

2009 – 2012

President of "European Association of Applied Immunology e.V."

2009 – 2012

Editor-in-Chief of "The Open Cancer Immunology Journal"

Publications

(This is not a complete list of publications, but only a selection of the major ones.)

Rajewsky K, Schirmacher V, Nose S, Jerne NK. The requirement of more than one antigenic determinant for immunogenicity. J Exp Med 1969, 129:1131-43. PMID: 4181830

Schirmacher V. Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis. Immunobiology 1980, 157:89-98. PMID: 6967852

Heicappell R, Schirmacher V, von Hoegen P, Ahlert T, Appelhans B. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int J Cancer 1986, 37:569-77. PMID: 3957462

Khazaie K, Prifti S, Beckhove P et al. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. *Proc Natl Acad Science USA* 1994, 91:7430-4. PMID: 8052600

Schirmmacher V, Beckhove P, Kruger A et al. Effective immune rejection of advanced metastasized cancer. *Int J Onco* 1995, 6:505-21. PMID: 21556565

Schirmmacher V, Forg P, Dalemans Wet 01. Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen. *Gene Ther* 2000,7:1137-47. PMID: 10918481

Feuerer M, Beckhove P, Bai L et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. *Nat Med* 2001, 7:452-8. PMID: 11283672

Bai L, Koopmann J, Fiola C et al. Dendritic cells pulsed with viral oncolysate stimulate autologous T-cells from cancer patients. *Int J Oncol* 2002, 21:685-94. PMID: 12239606

Feuerer M, Beckhove P, Garbi N et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. *Nat Med* 2003, 9:1151-7. PMID: 12910264

Steiner HH, Bonsanto MM, Beckhove P et al. Antitumor vaccination of patients with Glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. *J Clin Oncol* 2004, 22:4272-81. PMID: 15452186

Sommerfeldt N, Schiitz F, Sohn C et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. *Cancer Res* 2006, 66:8258-65. PMID: 16912206

Schirmmacher V. Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals. *Cancer Immunol Immunother* 2014,63:535-43. PMID: 24610041

Fournier P, Schirmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. *Biodrugs* 2013, 27:35-53. PMID: 23329400

Schirmacher V. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy: A biological agent with potential to break therapy resistance. *Exp Opin Bioi Ther* 2015, 15:1757-71. PMID: 26436571

Schirmacher V. Fifty years of clinical application of Newcastle disease virus. Time to celebrate! *Biomedicines* 2016, 4(3), 16. PMID: 28536382

Schirmacher V, Lorenzen D, Von Goel SW, Stuecker W. A new strategy of cancer immunotherapy combining hyperthermia/oncolytic virus pretreatment with specific autologous anti-tumor vaccination - A review. *Austin Oncol Case Rep* 2017, 2:1006.

Awards

1982

Aronson Preis

given by the Senate of Berlin

1982

Meyenburg-Preis

given by the Wilhelm and Maria Meyenburg-Stiftung

1988

Deutscher Krebs-Preis

given by the Deutsche Krebsgesellschaft e.V.